# (19) World Intellectual Property Organization

International Bureau



# 

(43) International Publication Date 18 November 2004 (18.11.2004)

**PCT** 

### (10) International Publication Number WO 2004/099410 A3

(51) International Patent Classification7: A61K 38/40

(21) International Application Number:

PCT/CA2004/000697

(22) International Filing Date:

7 May 2004 (07.05.2004)

(25) Filing Language:

English

(26) Publication Language:

**English** 

(30) Priority Data:

9 May 2003 (09.05.2003)

60/469,000

- (71) Applicant (for all designated States except US): TRANS-FERT PLUS [CA/CA]; 550 Sherbrooke West, Suite 100, Montréal, Québec\_H3A 1B9 (CA).
- (72) Inventors; and
- BELIVEAU, (75) Inventors/Applicants (for US only):


Richard [CA/CA]; 266, Wilson, Montréal, Québec H3E 1L8 (CA). DEMEULE, Michel [CA/CA]; 3557, Archambault, Longueuil, Québec J4M 2W8 (CA). BERTRAND, Yanick [CA/CA]; Apartment 6, 860, Marmier, Longuevil, Québec J4K 4S2 (CA). MICHAUD-LEVESQUE, Jonathan [CA/CA]; 7718, Berri, Montréal, Québec H2R 2G9 (CA). ROLLAND, Yannève [CA/CA]; 6554, Chabot, Montréal, Québec H2G 2T5 (CA). JODOIN, Julie [CA/CA]; 1965, Fullum, Montréal, Québec H2K 3N3 (CA).

- (74) Agent: OGILVY RENAULT LLP / S.E.N.C.R.L., S.R.L.; Suite 1600, 1981 McGill College Avenue, Montréal, Québec H3A 2Y3 (CA).
- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,

[Continued on next page]

### (54) Title: COMPOUND AND METHOD FOR REGULATING PLASMINOGEN ACTIVATION AND CELL MIGRATION

Pro-uPA and plasminogen interaction with soluble p97




Inhibition by mab 1235 Plasmin activity and cell migration pro-uPA mb p97

₿

(57) Abstract: The invention relates to novel regulators of plasminogen activation and their use for regulating cell migration, plasminolysis, angiogenesis, fibrinolysis, for treating cancer and thrombo-embolic diseases such as heart stroke. Furthermore, the present invention relates to novel pharmaceutical compositions regulating cell migration, plasminolysis, angiogenesis and for treating cancer. In particular, the present invention relates to a method of regulating the activation of plasminogen comprising contacting a solution of pro-urokinase (uPA) or tissue plasminogen activator (tPA) and plasminogen with melanotransferrin (p97) for a time sufficient to effect regulation thereof.

Competition of exogenous p97 for pro-uPA and plasminogen interaction



## WO 2004/099410 A3

- | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (111) | (11

MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

#### Published:

- with international search report
- (88) Date of publication of the international search report: 29 September 2005

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

PCT/CA2004/000697

A. CLASSIFICATION OF SUBJECT MATTER IPC 7 A61K38/40

According to International Patent Classification (IPC) or to both national classification and IPC

### **B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols) I PC  $\,\,7\,\,$  A  $\,61K$ 

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the International search (name of data base and, where practical, search terms used)

EPO-Internal, BIOSIS, Sequence Search

Category °	Citation of document, with Indication, where appropriate, of the relevant passages	Relevant to daim No.
Y	SALA ROBERTA ET AL: "The human melanoma associated protein melanotransferrin promotes endothelial cell migration and angiogenesis in vivo."  EUROPEAN JOURNAL OF CELL BIOLOGY, vol. 81, no. 11, November 2002 (2002-11), pages 599-607, XP009037961  ISSN: 0171-9335  Results: "MTf induces an angiogenic response in the chick embryo CAM", "Induction of endothelial cell migration by MTf is partly dependent on VEGF"; Discussion: Last paragraph  ———————————————————————————————————	4-7, 10-17, 22, 24-27, 29,32-41

Further documents are listed in the continuation of box C.	Patent family members are listed in annex.
Special categories of cited documents:      A* document defining the general state of the art which is not considered to be of particular relevance      E* earlier document but published on or after the international filing date      C* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)      O* document referring to an oral disclosure, use, exhibition or other means      P* document published prior to the international filing date but later than the priority date claimed	<ul> <li>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</li> <li>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</li> <li>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</li> <li>"&amp;" document member of the same patent family</li> </ul>
Date of the actual completion of the international search	Date of mailing of the International search report
28 October 2004	05/11/2004
Name and mailing address of the ISA	Authorized officer
European Patent Office, P.B. 5818 Patentlaan 2 NL – 2280 HV Rijswijk Tel. (+31–70) 340–2040, Tx. 31 651 epo nl, Fax: (+31–70) 340–3016	Page, M

PCT/CA2004/000697

C.(Continu	ation) DOCUMENTS CONSIDERED TO BE RELEVANT	
Category °		Relevant to claim No.
Y	US 6 455 494 B1 (JEFFERIES WILFRED A ET AL) 24 September 2002 (2002-09-24)	4-7, 10-17, 22, 24-27,
	paragraphs '0027!, '0028!, '0037!, '0130!, '0201!, '0203!, '0237!, '0458!	29,32-41
P,X	DEMEULE MICHEL ET AL: "Regulation of plasminogen activation: A role for melanotransferrin (p97) in cell migration." BLOOD, vol. 102, no. 5, 1 September 2003 (2003-09-01), pages 1723-1731, XP002300165 ISSN: 0006-4971 Results, page 1723, right-hand column, paragraph 2 page 1724, left-hand column, paragraph 1	1-41, 43-46, 48-51
А	ROSE T M ET AL: "PRIMARY STRUCTURE OF THE HUMAN MELANOMA-ASSOCIATED ANTIGEN P97 (MELANOTRANSFERRIN) DEDUCED FROM THE MRNA SEQUENCE" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 83, March 1986 (1986-03), pages 1261-1265, XP002934311 ISSN: 0027-8424 figure 3	1-54
Y	US 2002/119095 A1 (BROOKS ROBERT CHARLES ET AL) 29 August 2002 (2002-08-29) paragraph '0077!	6,7,12, 13,25, 26,34,35
A	SCHLINGEMANN R O ET AL: "EXPRESSION OF THE HIGH MOLECULAR WEIGHT MELANOMA-ASSOCIATED ANTIGEN BY PERICYTES DURING ANGIOGENESIS IN TUMORS AND IN HEALING WOUNDS"  AMERICAN JOURNAL OF PATHOLOGY, vol. 136, no. 6, 1990, pages 1393-1406, XP009037870 ISSN: 0002-9440 page 1403, left-hand column, paragraph 1	16,17, 39-41, 46,51

International application No. PCT/CA2004/000697

Box II	Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)
This Inte	ernational Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:
1. χ	Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:  Rule 39.1(iv) PCT — Method for treatment of the human or animal body by
	therapy
2	Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful international Search can be carried out, specifically:
3.	Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).
Box III	Observations where unity of invention is lacking (Continuation of item 3 of first sheet)
This Inte	ernational Searching Authority found multiple inventions in this international application, as follows:
1.	As all required additional search fees were timely paid by the applicant, this international Search Report covers all searchable daims.
2.	As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3.	As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4.	No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
Remari	The additional search fees were accompanied by the applicant's protest.  No protest accompanied the payment of additional search fees.

Information on patent family members

TCT/CA2004/000697

Patent document cited in search report		Publication date		Patent family member(s)	Publication date
US 6455494	B1	24-09-2002	US	5981194 A	09-11-1999
			US	2003077693 A1	24-04-2003
			US	2002119095 A1	29-08-2002
			ΑU	4553793 A	31-01-1994
			CA	2139862 A1	20-01-1994
			DE	69331100 D1	13-12-2001
			DE	69331100 T2	14-08-2002
			ΕP	0651768 A1	10-05-1995
			ΑT	269545 T	15-07-2004
			ΑU	717198 B2	23-03-2000
			AU	6783496 A	19-03-1997
			CA	2230372 A1	06-03-1997
			WO	9708560 A1	06-03-1997
			CN	1198214 A	04-11-1998
			DE	69632734 D1	22-07-2004
			EΡ	0847530 A1	17-06-1998
			ΙL	123441 A	11-01-2001
			JP	11511257 T	28-09-1999
			JP	3259963 B2	25-02-2002
			NZ	315997 A	30-08-1999
			WO	9401463 A1	20-01-1994
			EP	1018343 A1	12-07-2000
			EP	1143253 A1	10-10-2001
US 2002119095	A1	29-08-2002	US	6455494 B1	24-09-2002
			US	5981194 A	09-11-1999
			US	2003077693 A1	24-04-2003
			AT	269545 T	15-07-2004
			AU	717198 B2	23-03-2000
			AU	6783496 A	19-03-1997
			CA	2230372 A1	06-03-1997
			WO	9708560 A1	06-03-1997
			CN	1198214 A	04-11-1998
			DE	69632734 D1	22-07-2004
			EP	0847530 A1	17-06-1998
			ΙL	123441 A	11-01-2001
			JР	1151 1257 T	28-09-1999
			JP	3259963 B2	25-02-2002
			NZ	315997 A	30-08-1999
			AU	4553793 A	31-01-1994
			CA	2139862 A1	20-01-1994
			MO	9401463 A1	20-01-1994
			DE	69331100 D1	13-12-2001
			DE	69331100 T2	14-08-2002
			EP	1018343 A1	12-07-2000
			EP	1143253 A1	10-10-2001
			EP	0651768 A1	10-05-1995
			AU	8374001 A	25-02-2002
			AU	8502001 A	25-02-2002
			WO	0213843 A2	21-02-2002
			WO	0213873 A2	21-02-2002